- Home
- GPI vs SLS Comparison
GPI vs SLS Comparison
Compare GPI & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPI | SLS |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 1997 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GPI | SLS |
|---|---|---|
| Price | $240.26 | $11.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $346.42 | $32.50 |
| AVG Volume (30 Days) | 268.2K | ★ 4.4M |
| Earning Date | 10-28-2026 | 11-11-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 19.50 | N/A |
| Revenue | ★ $11,123,721,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $11.71 | ★ N/A |
| Revenue Growth | ★ 2.17 | N/A |
| 52 Week Low | $225.51 | $1.39 |
| 52 Week High | $461.27 | $15.88 |
Technical Indicators
Market Signals| Indicator | GPI | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 44.66 |
| Support Level | N/A | $10.78 |
| Resistance Level | $257.07 | $12.53 |
| Average True Range (ATR) | 9.17 | 0.66 |
| MACD | 0.15 | 0.06 |
| Stochastic Oscillator | 44.57 | 32.13 |
Price Performance
Historical ComparisonAbout GPI Group 1 Automotive Inc.
Group 1 owns and operates 32 collision centers and over 250 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 106 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.